Radical prostatectomy reduces mortality among men with clinically detected localized prostate cancer, but evidence from randomized trials with long-term followup is sparse.
T h e ne w e ngl a nd jou r na l o f m e dicine I n Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4), we compared radical prostatectomy with watchful waiting among men with localized prostate cancer. Enrollment, which began in 1989, predominantly included men with clinically detected tumors. In this follow-up study conducted 29 years after the start of the trial, at a point at which 80% of the men enrolled had died, we analyzed whether the survival benefit after radical prostatectomy continued, whether the benefit differed according to age at diagnosis, whether protocol violations had biased the results, and how many years of life, on average, had been saved for each man after radical prostatectomy. We also investigated whether histopathological variables predicted a long-term prognosis in the radical-prostatectomy group.
Me thods

Trial Design
Overall, 695 men with localized prostate cancer were randomly assigned to either radical prostatectomy or watchful waiting in 14 centers in Sweden, Finland, and Iceland between October 1989 and February 1999. The trial has been described in detail in previous publications, [1] [2] [3] [4] [5] and the protocol is available with the full text of this article at NEJM.org. The regional ethics committees at all the centers approved the trial. Men were included in the trial if they were younger than 75 years of age, had a life expectancy of more than 10 years and no other known cancer that was considered likely to shorten survival, had a prostate-specific antigen (PSA) level of less than 50 ng per milliliter, and had a localized tumor. 6 Tumors were required to be highly to moderately highly differentiated according to the World Health Organization classification, based on core biopsy or fine-needle aspiration. A negative bone scan was also required for eligibility.
Surgery started with removal of lymph nodes in the obturator fossa and continued if there were no nodal metastases detected in a frozen section. 7 If signs of local recurrence (a palpable nodule or histologically confirmed recurrence) developed in a patient in the radical-prostatectomy group, androgen-deprivation therapy was initiated. Confirmed metastases were treated hormonally in both groups. In 2003, androgen-deprivation treatment was allowed if tumor progression occurred, if the PSA level increased, or if the therapy was judged to be of potential clinical benefit. In 1999, all core-biopsy specimens were reviewed by four uropathologists and graded according to the Gleason system (scores range from 2 to 10 and are calculated as the sum of two scores [each ranging from 1 to 5] indicating the aggressiveness of the two most common histologic patterns in a prostate tumor, with higher scores indicating more aggressive cancer). 8 In 2006, the specimens from radical prostatectomy were reviewed and graded according to the Gleason system and evaluated for positive surgical margins and for extracapsular extension. 
Follow-up
Patients underwent a follow-up examination every 6 months for the first 2 years and then annually. Metastases were diagnosed at bone scan or were histologically confirmed at sites outside the pelvic area. In the radical-prostatectomy group, local recurrence was defined as a palpable mass on digital rectal examination or a histologically confirmed tumor on transrectal biopsy. In the watchful-waiting group, tumor progression was defined as palpable extracapsular extension or voiding obstruction that required intervention.
Causes of death were determined by an independent end-point committee whose members were unaware of the treatment assignments and who received extracted information according to a protocol. The members of the end-point committee individually determined the cause of death and reached consensus for cases initially classified differently. All participants were followed until December 31, 2017, and no patient was lost to follow-up.
Statistical Analysis
The end points we investigated were death from any cause, death from prostate cancer, and metastasis, with death from other causes treated as competing risk. Gray's test was used to assess treatment effects. 9 Effect sizes were quantified by analyzing relative risks (with 95% confidence intervals) and differences in cumulative incidence (with 95% confidence intervals). Relative risks were estimated from Cox proportional-hazards models in which proportionality was verified by visual inspection of Schoenfeld residuals. Cumulative-incidence proportions were used to account for competing risks among various causes of death.
10 Analyses were also stratified according to age at diagnosis (<65 years vs. ≥65 years). All Prostatectomy or Watchful Waiting in Prostate Cancer the men were followed until death or December 31, 2017, whichever came first. The median follow-up time was calculated with the use of the reverse Kaplan-Meier method. 11 Differences in residual mean survival time at 23 years were used to calculate the years of life gained.
12
A per-protocol analysis involving all the men who survived at least 1 year was performed and was based on treatments given during the first year. Men who were randomly assigned to radical prostatectomy and did not undergo the procedure and men who were randomly assigned to watchful waiting who underwent radical prostatectomy or lymph-node dissection during the first year were excluded from the per-protocol analysis. Data from men in the watchful-waiting group who later underwent surgery were censored. For the per-protocol analysis, we used a Cox regression with adjustment for baseline characteristics: age, tumor stage, PSA level, and Gleason score of the core-biopsy specimen. Missing data were imputed with the use of chained equations with five imputation data sets per value. 13 We assessed the prognostic value of margins (positive or negative), extracapsular tumor growth (not present or any extension), and Gleason score (2 to 6, 7 [separated into Gleason grade 3+4 and 4+3, with the latter designation indicating that grade 4 was the more common histologic pattern in the tumor], or 8 to 10) in the radical-prostatectomy specimens and expressed the results as relative risks obtained from multivariable Cox proportional-hazards models. One model included the histopathological measures one at a time and was adjusted for age group (<65 vs. ≥65 years). The other model included the histopathological measure of interest but was adjusted for the two other histopathological measures, for PSA level, and for age group.
R esult s
Patients
In all, 347 men were randomly assigned to the radical-prostatectomy group and 348 to the watchful-waiting group. The baseline characteristics of the two groups were similar, with a mean age of 65 years. Only 12% of the patients had nonpalpable stage T1c tumors at inclusion. The mean PSA level was approximately 13 ng per milliliter (Table 1) . By December 31, 2017, a total of 294 of the 347 men (85%) in the radicalprostatectomy group had undergone a radical prostatectomy, and 52 of the 348 men (15%) in the watchful-waiting group had undergone curative treatment (Fig. S1 in the Supplementary Appendix, available at NEJM.org). The median followup time was 23.6 years, the minimum follow-up time was 20 days, the maximum observed follow-up time was 28.0 years, and the maximum potential follow-up time was 29.3 years.
Mortality
Of the 695 men who were included in the analysis, 553 (80%) had died by the end of 2017. In 181 patients (32%), the deaths were due to prostate cancer (71 in the radical-prostatectomy group and 110 in the watchful-waiting group). One man in the radical-prostatectomy group died shortly after surgery. The cumulative incidence of death at 23 years was 71.9% in the radicalprostatectomy group and 83.8% in the watchfulwaiting group (difference, 12.0 percentage points; 95% confidence interval [CI], 5.5 to 18.4). The corresponding relative risk based on data for the complete follow-up period was 0.74 (95% CI, 0.62 to 0.87; P<0.001) ( Fig. 1 and Table 2, and  Table S1 in the Supplementary Appendix). The cumulative incidence of death from prostate cancer at 23 years was 19.6% in the radicalprostatectomy group and 31.3% in the watchfulwaiting group (difference, 11.7 percentage points; 95% CI, 5.2 to 18.2), and the relative risk for the complete follow-up period was 0.55 (95% CI, 0.41 to 0.74; P<0.001) ( Fig. 1 and Table 2, and  Table S1 in the Supplementary Appendix). The mean years of life gained in the radical-prostatectomy group at 23 years of follow-up was 2.9 years.
Distant Metastases
Distant metastases were diagnosed in 92 men in the radical-prostatectomy group and in 150 men in the watchful-waiting group. The cumulative incidence of distant metastases at 23 years was 26.6% in the radical-prostatectomy group and 43.3% in the watchful-waiting group (difference, 16.7 percentage points; 95% CI, 9.6 to 23.7). The relative risk based on data from the complete follow-up period was 0.54 (95% CI, 0.42 to 0.70; P<0.001) ( Fig. 2 and Table 2 ).
Analyses According to Age
The effect of radical prostatectomy among men who were younger than 65 years of age at diagnosis was greater than the effect on those who were older than 65 years with regard to all three ‖ Prostate-specific antigen (PSA) levels were assayed during opportunistic screening among asymptomatic men. ** Detection was coincidental during rectal examination being performed because of other symptoms. † † Category pertains to the year after randomization. ‡ ‡ A radical-prostatectomy specimen was not retrieved for 5 men.
T Tables 1 and 2 ).
Per-Protocol Analyses
The cumulative incidence of the end points and corresponding relative risks according to treatment received within the first year is shown in Table S2 
Long-Term Prognosis Based on Histopathological Measures in the Radical-Prostatectomy Group
A positive surgical margin was present in 99 (35%) of the 283 prostatectomy specimens that could be evaluated. A positive margin was associated with a poorer prognosis in the statistical model that had adjustment only for age, but when we adjusted for extracapsular extension, PSA level, and Gleason score, the relative risk of death from prostate cancer associated with positive margins as compared with clear margins was small (1.16; 95% CI, 0.62 to 2.15). Extracapsular extension was present in 132 (47%) of 283 reviewed specimens in the radicalprostatectomy group. A total of 38 of the men (29%) with extracapsular extension died from prostate cancer, as compared with 9 of the men (6%) without extracapsular extension, which corresponded to a relative risk of 5.21 (95% CI, 2.42 to 11.22). As compared with men who had a Gleason score of 3 to 6, the risk of death from prostate cancer among men with a Gleason score of 3+4 was similar (relative risk, 0.99; 95% CI, 0.23 to 4.33), but the risk among men with a Gleason score of 4+3 was 5 times as high (relative risk, 5.73; 95% CI, 1.59 to 20.67). Among men with a Gleason score of 8 or 9 in the radicalprostatectomy group (no men had a score of 10), the risk of death from prostate cancer was 10 times as high as that among men with a score of 3 to 6 (relative risk, 10.63; 95% CI, 3.03 to 37.30) ( Table 3) .
Discussion
After 29 years of follow-up, at a time when 80% of all the participants had died, lower overall mortality, lower mortality due to prostate cancer, and a lower risk of metastasis prevailed in the radical-prostatectomy group. The findings from a per-protocol analysis with adjustment for nonadherence to the assigned treatment did not differ from the main findings from the intention-to-treat analysis. At 23 years of follow-up, radical prostatectomy resulted in a mean of 2.9 years of life gained. Extracapsular extension and a Gleason score of 8 or 9 in the radical-prostatectomy group were strong predictors of death from prostate cancer.
In our trial, the absolute benefit associated with radical prostatectomy increased by a factor of more than 2 between 10 and 23 years of follow-up for both overall mortality (from 5.0 to 12.0 percentage points) and disease-specific mortality (from 5.5 to 11.7 percentage points), whereas the relative risks remained stable during this period for both overall mortality (0.75 to 0.74) and disease-specific mortality (0.56 to 0.54). 2 In the Prostate Cancer Intervention versus Observation Trial (PIVOT), at 19 years of follow-up, the relative risk of death from prostate cancer was 0.65 and thus similar to our results, but the absolute difference in risk was only 4 percentage points, reflecting the low baseline risk. 14 The difference in risk in PIVOT is similar to that in the SPCG-4 10-year follow-up analysis. Only longterm follow-up can reveal whether the PIVOT results will catch up with the SPCG-4 results after passing of the lead time associated with PSA testing or whether they will remain unchanged as a result of a substantial overdiagnosis of nonlethal prostate cancer.
In the Prostate Testing for Cancer and Treatment (ProtecT) trial, which involved only PSAdetected prostate cancers, the relative risk of death from prostate cancer at 10 years associated with radical prostatectomy as compared with Prostatectomy or Watchful Waiting in Prostate Cancer active monitoring was 0.63. 15 In that trial, the comparison group is not watchful waiting but active monitoring, and therefore the goal is to compare immediate radical treatment with delayed curative treatment in patients for whom it is indicated; in theory, this should reduce the possibility of finding any substantial effect from radical prostatectomy. The event rate is still low in the ProtecT trial, and only approximately 1% of the participants died from prostate cancer within 10 years, which suggests an even longer lead time and possibly a greater degree of overdiagnosis than in PIVOT.
The length of time for a more substantial benefit to occur even among men with more advanced tumors, as in our trial, highlights the importance of carefully selecting men who might benefit from curative treatment and not treating the small, low-risk tumors often diagnosed today, unless they show signs of progression during Other main cause, without androgen-deprivation therapy
Other main cause, with androgendeprivation therapy
Other main cause, with metastasis
Prostate cancer
T h e ne w e ngl a nd jou r na l o f m e dicine ‖ Death from other causes was considered as a competing risk in the analysis. ** Death from other causes without previous metastasis was considered as a competing risk in the analysis.
Prostatectomy or Watchful Waiting in Prostate Cancer
active surveillance. At this follow-up, neither the analysis stratified according to age nor the perprotocol analysis could corroborate that age per se plays a major role in the response to radical prostatectomy. However, the long latency period before effects become tangible and our estimates of years of life gained point toward the importance of taking the expected remaining lifetime into account when recommending treatment. Both our trial and PIVOT required participants to have at least 10 years of expected survival. However, in our trial, at 10.8 years of follow-up, 42% of the patients had died, and at 10 years in the PIVOT trial, 48% had died, reflecting the difficulty of estimating life expectancy. 2, 16 In the ProtecT trial, only 5% of the patients had died by 10 years, which partly reflects the steady increase in life expectancy in high-income countries. 15, 17 Metastasis to other sites
Bone metastasis Cumulative incidence of metastasis
T h e ne w e ngl a nd jou r na l o f m e dicine
In a trial with a drastic difference between the interventions, there is always a risk that the reasons for nonadherence will differ considerably according to trial group, which may bias the comparison. The per-protocol analysis in our trial showed results similar to those in the intentionto-treat analysis. Thus, our main results do not reflect the possible effects of systematic patterns of nonadherence.
A mean of 2.9 years of life were gained with radical prostatectomy. The mean number of years gained is a crude measure, since any given man who is randomly assigned to undergo the procedure either might not benefit at all or might have a much greater benefit than the mean number for the whole group indicates. However, the measure puts in perspective what is risked by delaying intervention. We have previously found similar quality of life after radical prostatectomy and watchful waiting. 18 In a recent publication, however, we investigated the effect of hormonal therapy and found that men whose prostate cancer is managed by watchful waiting without hormonal treatment reported the highest quality of life, which was similar to that among younger men without prostate cancer. In contrast, men who had disease progression while undergoing watchful waiting, which necessitated initiation of hormonal therapy, reported the lowest quality of life. 19 These findings help with individual counseling and shared decision making about the advantages and disadvantages of curative treatment.
Extracapsular extension and a high Gleason score in the prostatectomy specimen were strong predictors of death from prostate cancer; the majority of men who died from prostate cancer in the radical-prostatectomy group had extracapsular extension. More studies of adjuvant treatment are needed, but the strategies for the selection of patients and interventions are not self-evident: at 29 years of follow-up in our trial, only one third of the men with extracapsular extension had died from prostate cancer.
The strengths of our trial are the randomized design, the completeness of the long-term followup data, and the blinded evaluation of causes of death. Adherence to the assigned treatment was high, and a per-protocol analysis did not alter our main conclusions. Our interpretation of the data relies on estimates and trends consistent over an extended follow-up period. The limitations of our trial are that the analyses according to age were not prespecified in the protocol, were exploratory, and were, among other caveats, sensitive to chance findings and not adjusted for multiple testing. Furthermore, the diagnostic procedures used today differ drastically from those used during the period of enrollment in our trial. As a result of widespread PSA testing today, most men have nonpalpable, PSA-detected tumors, whereas in our trial the majority of the men had clinically detected, palpable tumors. Today, men undergo multiple biopsies or multiparametric magnetic resonance imaging with targeted biopsies, whereas the participants in our trial had only cytologic or sextant biopsies, with few cores investigated as compared with current standards. Today, the clinical domain of localized prostate cancer is different, and the sensitivity for the detection of high-grade cancers during our trial was considerably lower than it is today.
In clinically detected prostate cancer, the benefit of radical prostatectomy in otherwise healthy men can be substantial, with a mean gain of almost 3 years of life after 23 years of follow-up. The remaining expected lifetime is important in decision making, with the reservation that it is hard to predict. When our results are applied to inform current practice, several issues have to be considered: the lead time induced by screening, the addition to modern cohorts of overdiagnosed nonlethal cancers, and the influence of modern diagnostics on the definition of risk groups. Furthermore, even if the relative risks in our trial were fully applicable to modern studies, the amount of absolute benefit is highly dependent on baseline risk.
